Erenumab effective for nonopioid medication overuse headache in migraine patients

Monthly injections of 140 mg erenumab significantly reduced medication overuse headaches in patients with chronic migraines, demonstrating both efficacy and safety over a six-month period.

Study details and results

• This randomized, double-blind, placebo-controlled trial, conducted at 67 centers across North America, Europe, and Australia, included 620 adults with chronic migraine and medication overuse headaches (CM-MOH); 584 participants were in the nonopioid group and 36 were in the opioid group.
• Monthly injections of erenumab (70 mg or 140 mg) or placebo were administered for 24 weeks, with the primary outcome being MOH remission at month 6.
• At month 6, 69.1% of participants in the 140 mg erenumab group achieved remission compared with 52.6% in the placebo group. Adverse events in the active treatment arm were consistent with the known safety profile of erenumab.

Source:

Tepper SJ, et al. (2024, September 16). JAMA Neurol. Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/39283627/